Compare
Alumis Inc. vs Entrada Therapeutics, Inc. vs NewAmsterdam Pharma Co N.V. vs Celularity Inc
| Latest fiscal year | Alumis Inc. ALMS | Entrada Therapeutics, Inc. TRDA | NewAmsterdam Pharma Co N.V. NAMS | Celularity Inc CELU |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $24.05M | $25.42M | $22.50M | $26.55M |
| Revenue growth (YoY) | n/a | -87.9% | -50.6% | -51.0% |
| Gross margin | n/a | n/a | n/a | 24.4% (computed) |
| Operating margin | n/m | -621.1% | n/m | -230.9% |
| Net margin | n/m | -565.5% | -905.7% | -345.4% |
| Net income | -$243.32M | -$143.75M | -$203.82M | -$91.72M |
| EPS (Diluted) | -$2.86 | -$3.47 | -$1.72 | -$3.59 |
| Operating cash flow | -$369.52M | -$128.51M | -$147.78M | -$13.25M |
| Free cash flow | -$370.18M | -$129.55M | -$148.03M | n/a |
| Cash & equivalents | $89.67M | $90.39M | $490.00M | $6.17M |
| Total assets | $411.94M | $377.38M | $769.28M | $107.33M |
| Total liabilities | $110.64M | $71.25M | $85.85M | $145.39M |
| Shareholders' equity | $301.30M | $306.13M | $683.43M | -$38.06M |
| Return on year-end equity | -80.8% | -47.0% | -29.8% | n/a |
| Shares outstanding | n/a | 38.28M | 114.40M | 28.84M |
Revenue, most recent five fiscal years
| Fiscal year | Alumis Inc. | Entrada Therapeutics, Inc. | NewAmsterdam Pharma Co N.V. | Celularity Inc |
|---|---|---|---|---|
| Latest | $24.05M Ended 2025-12-31 | $25.42M Ended 2025-12-31 | $22.50M Ended 2025-12-31 | $26.55M Ended 2025-12-31 |
| 1 year earlier | n/a | $210.78M Ended 2024-12-31 | $45.56M Ended 2024-12-31 | $54.22M Ended 2024-12-31 |
| 2 years earlier | n/a | $129.01M Ended 2023-12-31 | $14.09M Ended 2023-12-31 | $22.77M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | $102.69M Ended 2022-12-31 | $17.98M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | n/a | $21.34M Ended 2021-12-31 |